Pneumonia News and Research

Latest Pneumonia News and Research

Universal surveillance for MRSA decreased HAIs related to devices: Study

Pitt County Memorial Hospital today announced results of a study demonstrating that universal surveillance for methicillin-resistant Staphylococcus aureus decreased health care-associated infections related to devices. Infection rates decreased 68 percent for ventilator-associated pneumonias; 51 percent for central line-associated bacteremias; and 49 percent for catheter-associated urinary tract infections.

14 Jul 2010

LSUHSC Professor awarded $2.1M grant to determine role of PCP

Dr. Jay Kolls, Professor and Chairman of Genetics at the LSU Health Sciences Center New Orleans School of Medicine, has been awarded a $2.1 million grant over five years by the National Heart, Lung, and Blood Institute of the National Institutes of Health to determine the role and identify which T-helper cells fight the opportunistic infection, Pneumocystis carinii pneumonia, which can be a complication of HIV/AIDS.

14 Jul 2010

AlphaRx reports positive preclinical results of GAI-122 injectable nanoemulsion for Acute Ischemic Stroke

AlphaRx, Inc. announced positive preclinical results of GAI-122 injectable nanoemulsion, a Mitochondria-targeted neuroprotective drug candidate being developed for the treatment of Acute Ischemic Stroke. The results will be delivered as a podium presentation during the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon July 10 - 14, 2010.

13 Jul 2010

Hospitals adopt advanced computer technology to prevent HAIs

Hospitals that adopt advanced computer technology to identify healthcare-associated infections are more likely to have implemented best practices to prevent such infections, according to research presented today at the 37th Annual Conference and International Meeting of the Association for Professionals in Infection Control and Epidemiology.

13 Jul 2010

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing and review the supplemental New Drug Application for SPRYCEL (dasatinib) for the treatment of adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.

12 Jul 2010

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from preclinical toxicology and pharmacokinetic studies of an intravenous (IV) formulation of its novel antibiotic, Restanza™ that support its use in a hospital setting.

8 Jul 2010

New information about quality of care available in America's hospitals added to new HHS website

Important new information about the quality of care available in America's outpatient and emergency departments, including how well hospitals care for patients with heart attacks and protect outpatients from surgical infections was added to the new HHS website HealthCare.gov.

8 Jul 2010

Heart attack death rates drop in hospitals; CDC reports increase in colon cancer screening rate

USA Today: Hospital heart attack death rates fell, according to new Medicare data. "Death rates at 4,569 hospitals that treat Medicare patients who suffer heart attacks fell by almost half a percentage point, from a national average of 16.6% last year to 16.2%. Death rates for most hospitals ranged from about 14.5% to 17.9%. ...

8 Jul 2010

HQA applauds public availability of hospital quality information at Hospital Compare website

The Hospital Quality Alliance today applauded the public availability of new information on hospital quality of care at the Hospital Compare website. The HQA is a broad working group of hospitals, consumer representatives, physician and nursing organizations, employers and payers, oversight organizations and government agencies dedicated to improving health care quality and making useful and understandable information about hospital quality available to the public.

8 Jul 2010

Study reveals asthma as a risk factor for pneumonia in children hospitalized for influenza

Children with asthma are at increased risk of developing pneumonia as a complication of influenza, reports a study in the July issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

8 Jul 2010

First Edition: July 7, 2010

Today's biggest health policy news surrounds an announcement by the White House that President Obama will install a new Medicare and Medicaid chief with a recess appointment the bypasses the confirmation process.

7 Jul 2010

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has reacquired all development and commercial rights to its high-mobility group box protein 1 (HMGB1) related technology from MedImmune, LLC.

6 Jul 2010

Pay-for-performance program may cause inequalities among healthcare providers

Pay-for-performance is an increasingly popular approach to improving health care quality. But the planned nationwide implementation of institutional bonuses mandated under federal health care reform threatens to act as a "reverse Robin Hood," potentially causing hospitals in less-advantaged regions to lose funds to health care facilities in more affluent areas of the country, according to a study published in the academic journal PLoS Medicine.

2 Jul 2010

Advanced Life Sciences prices securities offering

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has established the pricing terms of its proposed offering of units.

1 Jul 2010

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai Inc. announced today preliminary results from a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection versus either a low-dose chemotherapy agent or supportive care in elderly patients with acute myeloid leukemia (AML), a life-threatening cancer of the blood that generally occurs in older adults.

1 Jul 2010

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced the enrollment of the first patient in a Phase 2 study with CXA-201. This multicenter, double-blind, randomized, study will compare the safety and efficacy of intravenous CXA-201 with an active comparator in patients with complicated intra-abdominal Infections (cIAI). This international study is expected to enroll 120 patients.

1 Jul 2010

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.

30 Jun 2010

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that the recently-completed Phase 2 study of CXA-101, a novel cephalosporin, compared to ceftazidime for the treatment of complicated urinary tract infections (cUTI) in adults met its study objectives.

30 Jun 2010

Successful growth of mouse embryonic stem cells in rat lungs raises hopes for engineering human transplants

For someone with a severe, incurable lung disorder such as cystic fibrosis or chronic obstructive pulmonary disease, a lung transplant may be the only chance for survival. Unfortunately, it's often not a very good chance. Matching donor lungs are rare, and many would-be recipients die waiting for the transplants that could save their lives.

29 Jun 2010

AlphaRx regains all rights to Indaflex from Cypress Bioscience

AlphaRx, Inc. today announced that it has entered into an agreement with Cypress Bioscience, under which AlphaRx is regaining all rights to Indaflex(TM) from Cypress Bioscience, which AlphaRx had previously licensed to Proprius Pharmaceuticals, which was subsequently acquired by Cypress Bioscience.

29 Jun 2010

Pneumonia News and Research

Latest Pneumonia News and Research

Universal surveillance for MRSA decreased HAIs related to devices: Study

LSUHSC Professor awarded $2.1M grant to determine role of PCP

AlphaRx reports positive preclinical results of GAI-122 injectable nanoemulsion for Acute Ischemic Stroke

Hospitals adopt advanced computer technology to prevent HAIs

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

New information about quality of care available in America's hospitals added to new HHS website

Heart attack death rates drop in hospitals; CDC reports increase in colon cancer screening rate

HQA applauds public availability of hospital quality information at Hospital Compare website

Study reveals asthma as a risk factor for pneumonia in children hospitalized for influenza

First Edition: July 7, 2010

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Pay-for-performance program may cause inequalities among healthcare providers

Advanced Life Sciences prices securities offering

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Successful growth of mouse embryonic stem cells in rat lungs raises hopes for engineering human transplants

AlphaRx regains all rights to Indaflex from Cypress Bioscience

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Pneumonia News and Research

Latest Pneumonia News and Research

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in